Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04206436 · ClinicalTrials.gov registry record
CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis
A clinical trial of Cystic Fibrosis and Bone Loss, sponsored by Indiana University.
- Active
- Registry status
- 63
- Enrollment target
- 1
- Study location
NCT04206436: Active study of Cystic Fibrosis and Bone Loss, sponsored by Indiana University.
NCT04206436 is a study of Cystic Fibrosis and Bone Loss that is active but no longer recruiting, run by Indiana University. The registered enrollment target is 63 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04206436, a study of Cystic Fibrosis and Bone Loss, is active but no longer recruiting, sponsored by Indiana University.
- ACTIVE NOT RECRUITING
- Registry status
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
Study is looking at the effects of cystic fibrosis treatment on bone muscle.
Primary Outcome
Changes from baseline to 12 month in total volumetric BMD and in estimated failure load as measured by HRpQCT at the distal radius and tibia
Conditions Studied
Interventions
- DRUG Cftr Modulators
Study Locations (1)
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2019-12-18 |
| Est. Completion | 2027-12-31 |
What the registry record for NCT04206436 still lists
NCT04206436 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Cftr Modulators is the first listed.
NCT04206436 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT04206436 about?
NCT04206436 is a clinical study titled "CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis". Study is looking at the effects of cystic fibrosis treatment on bone muscle.
What is the current status of trial NCT04206436?
This trial is currently active not recruiting. The enrollment target is 63 participants. The study started on 2019-12-18. Estimated completion is 2027-12-31.
What conditions does trial NCT04206436 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Bone Loss, Muscle Loss.
What interventions are being tested in trial NCT04206436?
The interventions under investigation include: Cftr Modulators (DRUG).
Who is sponsoring clinical trial NCT04206436?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04206436 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04206436's enrollment target sits among peer trials
63 78th of 169 higher than 91 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI